Outlier in BE study [Study As­sess­ment]

posted by Amira Gouda – Egypt, 2020-04-29 14:35 (183 d 13:39 ago) – Posting: # 21364
Views: 2,244

Dear Ohlbe

Thanks for your reply

» Do you mean to say that these subjects did not have any sample collected later than 12 hours, or that their concentration was BLQ after 12 hours ?

ِActually, the first case is our case the subject did not have any sample collected later than 12 hours which occurred in phase 1 (and he consumed reference product),
our protocol stated that dropouts and withdrawals will be included in pk, not statistics.
the subject had completed the 2 phases due to sample size issues also the product half-life is a wide range, not a definite number.
we analyzed all samples, but now:
  1. if we exclude the subject and when submitting the study to RA, is this exclusion will be not accepted as the results of statistics including him is highly different?
  2. I will need supportive data from guidelines for this issue specifically, could you please help me if there is?
  3. Is re-dosing/re-testing of the subject with controls, could be supportive in this situation?

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]

Complete thread:

 Admin contact
21,179 posts in 4,414 threads, 1,474 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).
Forum time: Friday 04:15 UTC (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz